Further studies are needed to validate the benefit of SGLT2 inhibitors in reducing pneumonia, pneumonia-related mortality, and sepsis in patients with Type 2 diabetes and to clarify their mechanism of action. Here, SLC5A2 is linked to type 2 diabetes mellitus.